Tech Company Financing Transactions

Epizyme Funding Round

Amgen Ventures, Bay City Capital and Kleiner Perkins Caufield & Byers participated in a $32 million Series B venture round for Epizyme. The round was recorded on 10/7/2009.

Transaction Overview

Company Name
Epizyme
Announced On
10/7/2009
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series B
Investors

Amgen Ventures

Bay City Capital (Carl Goldfischer)

Kleiner Perkins Caufield & Byers (Beth Seidenberg)

MPM Capital (Kazumi Shiosaki)

Proceeds Purpose
Rapid progress has been made at Epizyme in evolving a robust pipeline of first-in-class inhibitors of histone methyltransferase (HMT) enzymes involved in cancer," said Epizyme chief executive officer Kazumi Shiosaki, PhD. "With the support of our new investors as well as our existing investors, we are now in a position to progress a number of these lead programs into proof-of-concept studies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 4th Floor
Cambridge, MA 02139
USA
Phone
(617) 229-5872
Website
www.epizyme.com
Email Address
[email protected]
Overview
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company?s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs).
Profile
Epizyme LinkedIn Company Profile
Social Media
Epizyme Company Twitter Account
Company News
Epizyme News
Facebook
Epizyme on Facebook
YouTube
Epizyme on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Robert Bazemore
  Robert Bazemore LinkedIn Profile  Robert Bazemore Twitter Account  Robert Bazemore News  Robert Bazemore on Facebook
Chief Financial Officer
Paolo Tombesi
  Paolo Tombesi LinkedIn Profile  Paolo Tombesi Twitter Account  Paolo Tombesi News  Paolo Tombesi on Facebook
Chief Medical Officer
Shefali Agarwal
  Shefali Agarwal LinkedIn Profile  Shefali Agarwal Twitter Account  Shefali Agarwal News  Shefali Agarwal on Facebook
Chief Operating Officer
Matthew Ros
  Matthew Ros LinkedIn Profile  Matthew Ros Twitter Account  Matthew Ros News  Matthew Ros on Facebook
VP - General Counsel
John Weidenbruch
  John Weidenbruch LinkedIn Profile  John Weidenbruch Twitter Account  John Weidenbruch News  John Weidenbruch on Facebook
VP - Regulatory Affairs
Mark De Rosch
  Mark De Rosch LinkedIn Profile  Mark De Rosch Twitter Account  Mark De Rosch News  Mark De Rosch on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/7/2009: Daptiv venture capital transaction
Next: 10/7/2009: Engine Yard venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.